A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Patients testing a new weight-loss drug developed by the creators of Ozempic have revealed the extreme effects it had on their bodies. Danish pharma giant Novo Nordisk has been tight-lipped ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Share on Pinterest Ozempic (semaglutide) is a medication approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. Because Ozempic has been shown to boost weight loss in people ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure ...

AS DEMAND GOES UP.. BUT HE SA Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the U.S. Food and Drug Administration to ...

with about 40% of people with type 2 also suffering from CKD. With the approval, doctors can prescribe Ozempic specifically to treat CKD in diabetic patients, The New York Times reported.

Ozempic: Which Is Better for Weight ... tirzepatide on more than 11,000 people with type 2 diabetes. It found that doses of 5 milligrams (mg), 10 milligrams and 15 milligrams led to weight loss.